Medical demo: Within a phase Ib trial, people with advanced strong tumors are addressed with weekly paclitaxel and escalating doses of oral PLX3397 to determine a RP2D of PLX3397. Determined by comparisons across species, the window of vulnerability to these adjustments is considered to correlate